Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Dmitry Tabakov"'
Autor:
Anastasiya Yudina, Alexey Efremov, Danielle Sookiasian, Ekaterina Nuzhdina, Svetlana Podsvirova, Madison Chasse, Tori Conroy, Noel English, Sergey Starikov, Olesia Klimchuk, Dmitry Tabakov, Anna Love, Kushal Suryamohan, Artur Baisangurov, Cagdas Tazearslan, Nathan Fowler, Alexander Bagaev
Publikováno v:
Cancer Research. 83:1042-1042
Minimally invasive next-generation sequencing-based (NGS) liquid biopsy (LB) tests using cell-free DNA (cfDNA) are increasingly becoming an important tool for the clinical management of cancer patients. The ability to accurately detect molecular alte
Autor:
Elena Ocheredko, Nadezhda Lukashevich, Maria Savchenko, Sofia Kust, Syune Ambaryan, Dmitry Tabakov, Maria Sorokina, Linda Balabanian, Kushal Suryamohan, Anastasiya Zotova, Nathan Fowler, Aleksander Bagaev
Publikováno v:
Cancer Research. 83:6538-6538
Functional gene expression signatures (FGES) are widely used as biomarkers in cancer diagnostics as descriptive and predictive models for treatment selection. Since FGES scores are based solely on gene expression profiles, they can be applied to data
Autor:
Zoya Antysheva, Maria V. Guryleva, Ivan Valiev, Nikita Kotlov, Viktor Svekolkin, Olga Gancharova, Vladimir Kushnarev, Yuriy Popov, Anna Belozerova, Dmitry Tabakov, Jessica H. Brown, Krystle Nomie, Alexander Bagaev, Nathan Fowler
Publikováno v:
Cancer Research. 82:1227-1227
Classifying tumors based on histological grade is used for many cancers to determine a patient’s prognosis and select the appropriate treatment. Although low grade (G1) and high grade (G3/G4) tumors have been shown to predict patient survival in ma
Autor:
Svetlana Shishkova, Dmitry Tabakov, Evgeny Egorov, Akshaya Ramachandran, Yang Lyu, Krystle Nomie, Jessica Brown, Vladimir Zyrin, Alexander Zaytcev, Natalia Miheecheva, Ekaterina Postovalova, Alexander Bagaev, Ravshan Ataullakhanov, James Hsieh
Publikováno v:
Cancer Research. 82:2061-2061
Checkpoint immunotherapy (CPI) and its combination with tyrosine kinase inhibitor (TKI) therapy are widely used in the treatment of many cancers, including clear cell renal cell carcinoma (ccRCC). Although recent advances in these therapies demonstra
Autor:
Elena N. Zakharova, Lev V. Demidov, Ekaterina Shakhray, Tatiana Zabotina, Natalia N. Petenko, Igor Samoylenko, Sergey Berdnikov, Dmitry Tabakov, Olga V. Korotkova
Publikováno v:
Journal of Clinical Oncology. 37:e14171-e14171
e14171 Background: We previously reported that aPD1 agents could be safely administered IL in patients (pts) with metastatic MEL with superficial lesions, providing local and bystander tumor response (Samoylenko, I., et al. (ASCO-SITC 2018)). We pres